Lupin Limited’s shares rose 3.25 per cent after the company secured an approval from the USFDA for its Abbreviated New Drug Application, allowing the marketing of Loteprednol Etabonate Ophthalmic Suspension-0.2%.
The newly approved generic equivalent serves as an alternative to Bausch & Lomb Inc’s reference listed drug, Alrex Ophthalmic Suspension, 0.2%.
Lupin will manufacture the product at its facility in Pithampur, India. Loteprednol Etabonate Ophthalmic Suspension, 0.2%, is designed for the temporary relief of signs and symptoms associated with seasonal allergic conjunctivitis. The reference product, RLD Alrex, achieved an estimated annual sales figure of $29.1 million in the U.S. as of October 2023 (IQVIA MAT).
The shares rose 3.25 per cent to ₹1,330.90 at 2.48 pm on the BSE.